Biotech Values

[genisi]

Peter, the editorial on lorcaserin data titled - Drug Management of Obesity — Efficacy versus Safety

http://content.nejm.org/cgi/content/short/363/3/288

was also kind of positive:

Lorcaserin therapy also resulted in slight, but clinically relevant, improvements in almost all reported surrogate measures of diabetes and cardiovascular risk. These findings are important in light of the problems with drugs such as rimonabant and sibutramine, which do not produce similar reductions in blood pressure, heart rate, and levels of low-density lipoprotein cholesterol that would be expected with the weight loss achieved.
...The justification for using lorcaserin to manage obesity is not greater efficacy than currently available drugs, but rather an apparently much better safety and adverse-event profile and very clear-cut beneficial effects on risk factors for type 2 diabetes and cardiovascular disease.